Historical Valuation
Aclaris Therapeutics Inc (ACRS) is now in the Fair zone, suggesting that its current forward PS ratio of 35.11 is considered Fairly compared with the five-year average of -6.56. The fair price of Aclaris Therapeutics Inc (ACRS) is between 0.75 to 8.36 according to relative valuation methord.
Relative Value
Fair Zone
0.75-8.36
Current Price：2.68
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Aclaris Therapeutics Inc (ACRS) has a current Price-to-Book (P/B) ratio of 2.60. Compared to its 3-year average P/B ratio of 1.77 , the current P/B ratio is approximately 46.51% higher. Relative to its 5-year average P/B ratio of 4.06, the current P/B ratio is about -36.04% higher. Aclaris Therapeutics Inc (ACRS) has a Forward Free Cash Flow (FCF) yield of approximately -13.78%. Compared to its 3-year average FCF yield of -37.31%, the current FCF yield is approximately -63.06% lower. Relative to its 5-year average FCF yield of -24.54% , the current FCF yield is about -43.83% lower.
P/B
Median3y
1.77
Median5y
4.06
FCF Yield
Median3y
-37.31
Median5y
-24.54
Competitors Valuation Multiple
AI Analysis for ACRS
The average P/S ratio for ACRS competitors is 7.79, providing a benchmark for relative valuation. Aclaris Therapeutics Inc Corp (ACRS.O) exhibits a P/S ratio of 35.11, which is 350.72% above the industry average. Given its robust revenue growth of -24.09%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ACRS
1Y
3Y
5Y
Market capitalization of ACRS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ACRS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ACRS currently overvalued or undervalued?
Aclaris Therapeutics Inc (ACRS) is now in the Fair zone, suggesting that its current forward PS ratio of 35.11 is considered Fairly compared with the five-year average of -6.56. The fair price of Aclaris Therapeutics Inc (ACRS) is between 0.75 to 8.36 according to relative valuation methord.
What is Aclaris Therapeutics Inc (ACRS) fair value?
ACRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aclaris Therapeutics Inc (ACRS) is between 0.75 to 8.36 according to relative valuation methord.
How does ACRS's valuation metrics compare to the industry average?
The average P/S ratio for ACRS's competitors is 7.79, providing a benchmark for relative valuation. Aclaris Therapeutics Inc Corp (ACRS) exhibits a P/S ratio of 35.11, which is 350.72% above the industry average. Given its robust revenue growth of -24.09%, this premium appears unsustainable.
What is the current P/B ratio for Aclaris Therapeutics Inc (ACRS) as of Jan 09 2026?
As of Jan 09 2026, Aclaris Therapeutics Inc (ACRS) has a P/B ratio of 2.60. This indicates that the market values ACRS at 2.60 times its book value.
What is the current FCF Yield for Aclaris Therapeutics Inc (ACRS) as of Jan 09 2026?
As of Jan 09 2026, Aclaris Therapeutics Inc (ACRS) has a FCF Yield of -13.78%. This means that for every dollar of Aclaris Therapeutics Inc’s market capitalization, the company generates -13.78 cents in free cash flow.
What is the current Forward P/E ratio for Aclaris Therapeutics Inc (ACRS) as of Jan 09 2026?
As of Jan 09 2026, Aclaris Therapeutics Inc (ACRS) has a Forward P/E ratio of -5.22. This means the market is willing to pay $-5.22 for every dollar of Aclaris Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aclaris Therapeutics Inc (ACRS) as of Jan 09 2026?
As of Jan 09 2026, Aclaris Therapeutics Inc (ACRS) has a Forward P/S ratio of 35.11. This means the market is valuing ACRS at $35.11 for every dollar of expected revenue over the next 12 months.